Bizarre Patents
A beach chair which can be adapted for a woman who is pregnant and wishes to sunbathe in the prone position.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Application No. | Application Title | Issue Date |
| 20120128772 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS OF MILNACIPRAN A controlled release pharmaceutical composition comprising Milnacipran or pharmaceutically acceptable salts thereof and hydrophobic release controlling agent. The composition releases 90% of the total amount of Milnacipran or pharmaceutically acceptable salts thereof be... | 05/24/2012 |
| 20120128771 | TIMED, PULSATILE RELEASE SYSTEMS A unit multiparticulate dosage form for delivering one or more basic, active pharmaceutical ingredients into the body in need of such medications to achieve target PK (pharmacokinetics) profiles is described. The dosage form comprises one or more multicoated drug partic... | 05/24/2012 |
| 20120045508 | METHOD AND COMPOSITION FOR ADMINISTERING AN NMDA RECEPTOR ANTAGONIST TO A SUBJECT The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject.... | 02/23/2012 |
| 20110287096 | MODIFIED GASTRORETENTIVE DRUG DELIVERY SYSTEM FOR AMINE DRUGS Oral dosage forms for basic amine drugs, the dosage forms having a gastro-retentive component and a non gastro-retentive component. These dosage forms are capable of providing both IR and SR release rates for these drugs. In addition, they provide for release of the dru... | 11/24/2011 |
| 20110280939 | ORAL PARTICLE INCLUDING PSEUDOEPHEDRINE HYDROCHLORIDE AND CETIRIZINE DIHYDROCHLORIDE The present invention relates to an oral particle including pseudoephedrine hydrochloride and cetirizine dihydrochloride, which primarily includes a nucleus having a diameter ranging 25˜40 mesh, a pseudoephedrine-hydrochloride layer coated outside the nucleus with a co... | 11/17/2011 |
| 20110262535 | Low Dose Topiramate / Phentermine Composition and Methods of Use Thereof A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in the range of 2 mg to 8 mg, in combination with a daily dose of topiramate... | 10/27/2011 |
| 20110229566 | Single Unit Oral Dose Pharmaceutical Composition Comprising Levodopa, Carbidopa And Entacapone Or Salts Thereof There is provided a single unit oral dose pharmaceutical composition comprising a) levodopa or salts thereof from about 50 mg to about 300 mg in extended release form, b) carbidopa or salts thereof from about 10 mg to about 100 mg in extended release and c) entacapone o... | 09/22/2011 |
| 20110223247 | PHARMACEUTICAL COMPOSITIONS FOR RELEASE CONTROL OF METHYLPHENIDATE Disclosed is a pharmaceutical composition for release control comprising a plurality of particles for release control. The plurality of particles for release control comprise a core material containing methylphenidate and a polymer coating layer for release control form... | 09/15/2011 |
| 20110189273 | AMANTADINE COMPOSITIONS AND METHODS OF USE Methods of nighttime administration of amantadine to reduce sleep disturbances in patient undergoing treatment with amantadine are described, as well as compositions of extended release amantadine that are suitable for nighttime administration.... | 08/04/2011 |
| 20110123613 | EXTENDED-RELEASE DOSAGE FORM Provided are pharmaceutical formulations comprising sustained release particles each having an inner core bead comprising an active pharmaceutical ingredient an intermediate coating substantially surrounding the inner core bead, and an outer coating substantially surrou... | 05/26/2011 |
| 20110117192 | CARBIDOPA/LIPODOPA GASTRORETENTIVE DRUG DELIVERY A gastroretentive drug formulation for the sustained release of an active agent in the gastrointestinal tract comprises an internal layer or compartment comprising an active agent and one or more pharmaceutical excipients, of which at least one is a polymer and two memb... | 05/19/2011 |
| 20110091542 | BACLOFEN AND R-BACLOFEN GASTRORETENTIVE DRUG DELIVERY SYSTEMS A biodegradable, multi-layered controlled release gastroretentive baclofen or R-baclofen dosage form which is optionally divided into a first dosage of baclofen or R-baclofen for immediate release and a second dosage of baclofen or R-baclofen for controlled release in t... | 04/21/2011 |
| 20110064804 | Methods and Compositions for the Treatment of CNS-Related Conditions The present invention provides novel methods and compositions for the treatment and prevention of CNS-related conditions. One of the CNS-related conditions treated by the methods and compositions of the invention is Alzheimer's disease.... | 03/17/2011 |
| 20110064803 | NANOPARTICULATE AND CONTROLLED RELEASE COMPOSITIONS COMPRISING VITAMIN K2 The present invention is directed to compositions comprising a nanoparticulate vitamin K2 having improved bioavailability. The nanoparticulate vitamin K2 particles of the composition have an effective average particle size of less than about 2000 nm and are useful in th... | 03/17/2011 |
| 20100272797 | Pharmaceutical Composition for Treating Hepatitis C Virus Infection Comprising HMG-COA Reductase Inhibitor and Bile Acid Disclosed herein is a pharmaceutical composition for treating hepatitis C virus infection comprising an HMG-CoA reductase inhibitor and bile acid. More specifically, disclosed are a pharmaceutical composition for treating hepatitis C vims infection comprising fluvastati... | 10/28/2010 |
| 20100270183 | STABLE DIGESTIVE ENZYME COMPOSITIONS Compositions of the present invention, comprising at least one digestive enzyme (e.g., pancrelipase) are useful for treating or preventing disorders associated with digestive enzyme deficiencies. The compositions of the present invention can comprise a plurality of coat... | 10/28/2010 |
| 20100266684 | METHOD AND COMPOSITION FOR ADMINISTERING AN NMDA RECEPTOR ANTAGONIST TO A SUBJECT The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject.... | 10/21/2010 |
| 20100260838 | METHOD AND COMPOSITION FOR ADMINISTERING AN NMDA RECEPTOR ANTAGONIST TO A SUBJECT The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject.... | 10/14/2010 |
| 20100189782 | Compositions Comprising Carisoprodol and Methods of Use Thereof The present invention provides compositions comprising carisoprodol or pharmaceutically acceptable salts, esters or derivatives thereof. In certain embodiments, the invention provides pharmaceutical compositions comprising the skeletal muscle relaxant carisoprodol and o... | 07/29/2010 |
| 20100151015 | Compositions Comprising Melperone and Controlled-Release Dosage Forms The present invention is directed to pharmaceutical compositions, and methods of making such compositions, comprising microparticles containing a core comprising melperone and a controlled-release coating. The present invention is also directed to pharmaceutical dosage ... | 06/17/2010 |
| 20100086588 | COMPOSITIONS AND METHODS FOR TREATMENT OF BOWEL DISEASES WITH GRANULATED MESALAMINE Disclosed are methods for treating gastrointestinal disorders, e.g., Crohn's disease, ulcerative colitis, and diverticular disease, with a granulated mesalamine formulation. Some formulations use granulated mesalamine in capsule form. Also included are methods to extend... | 04/08/2010 |
| 20100068267 | COMPOSITIONS FOR TREATING VASCULAR DISEASES CHARACTERIZED BY NITRIC OXIDE INSUFFICIENCY The invention provides methods of treating a cardiovascular disease comprising administering a sustained release formulation of hydralazine hydrochloride and at least one of isosorbide dinitrate and/or isosorbide mononitrate in therapeutically effective dosage of each o... | 03/18/2010 |
| 20100055177 | MODIFIED RELEASE COMPOSITION OF LEVETIRACETAM AND PROCESS FOR THE PREPARATION THEREOF Provided are modified release levetiracetam compositions, and processes for preparing them.... | 03/04/2010 |
| 20100052900 | SYSTEM TO MONITOR THE INGESTION OF MEDICINES A system for monitoring ingestion of medicine (21) comprises forming a digestible radio frequency identification (RFID) tag (10). The RFID tag is attached to the medicine. The RFID tag and medicine are ingested. A signal from the RFID tag is monitored.... | 03/04/2010 |
| 20100047342 | Method and Composition for Administering an NMDA Receptor Antagonist to a Subject The invention provides methods and compositions for administering an NMDA receptor antagonist (e.g., memantine) to a subject.... | 02/25/2010 |
| 20100047341 | COMBINED PREPARATION FOR THE TREATMENT OF CARDIOVASCULAR DISEASES BASED ON CHRONOTHERAPY THEORY The present invention relates to a functional combination preparation comprising a dihydropyridine-based calcium channel blocker such as amlodipine and an ARB (Angiotensin-2 receptor blocker) such as losartan. In particular, the present invention relates to a chronother... | 02/25/2010 |
| 20100040680 | MULTIPARTICULATE SELECTIVE SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITOR FORMULATION A multiparticulate oral pharmaceutical composition that contains a plurality of delayed release coated selective serotonin and norepinephrine reuptake inhibitor particles.... | 02/18/2010 |
| 20100021537 | Stable digestive enzyme compositions Compositions of the present invention, comprising at least one digestive enzyme (e.g., pancrelipase) are useful for treating or preventing disorders associated with digestive enzyme deficiencies. The compositions of the present invention can comprise a plurality of coat... | 01/28/2010 |
| 20090238867 | Nanoparticulate Anidulafungin Compositions and Methods for Making the Same Nanoparticulate compositions comprising anidulafungin are described, as well as methods of making such compositions. Also described are methods for treatment of fungal infections.... | 09/24/2009 |
| 20090214640 | DELAYED RELEASE PHARMACEUTICAL ORAL DOSAGE FORM AND METHOD OF MAKING SAME The present invention relates to a delayed release pharmaceutical oral dosage form and method of making same. The delayed release dosage form comprises one or more active ingredients within a granulated composition, which further comprises one or more excipients selecte... | 08/27/2009 |
| 20090181081 | Systemic Treatment of Pathological Conditions Resulting From Oxidative Stress and/or Redox Imbalance Alterations of redox homeostasis in mammals underlie a host of symptoms, syndromes and diseases, including AIDS and cancer, which can be successfully treated by administration to a mammal of therapeutically-effective amounts of sulfide compounds and/or thiosulfate compo... | 07/16/2009 |
| 20090169617 | Controlled Release Formulations Comprising Uncoated Discrete Unit(s) and an Extended Release Matrix A controlled-release formulation comprising one or more distinct and discrete units located in physical juxtaposition to enable administration to a patient in need of treatment in a single dose, characterised in that the or each unit comprise(s): (i) a unit dose of an a... | 07/02/2009 |
| 20090169619 | CARBAMAZEPINE EXTENDED RELEASE DOSAGE FORM Extended release pharmaceutical dosage forms of carbamazepine for oral administration to maintain a patient's blood concentration for at least a 12 hour period, methods of administering dosage forms and processes for the preparation of such dosage form.... | 07/02/2009 |
| 20090169618 | Zolpidem pharmaceutical compositions The present invention provides extended release pharmaceutical compositions comprising zolpidem or a salt thereof.... | 07/02/2009 |
| 20090123536 | Oral Pharmaceutical Form of Losartan The field of the present invention is that of oral pharmaceutical forms of losartan, and also treatments and administration methods relating thereto. The invention relates to the use, in an oral pharmaceutical form comprising losartan, of a... | 05/14/2009 |
| 20090092658 | NOVEL FORMULATIONS OF PROTON PUMP INHIBITORS AND METHODS OF USING THESE FORMULATIONS The present invention relates to combinations of a proton pump inhibiting agent and at least one buffering agent that have been found to possess improved bioavailability, chemical stability, physical stability, dissolution profiles, disintegration times, as well as othe... | 04/09/2009 |
| 20090060994 | Controlled release azithromycin solid dosages forms A solid dosage form for oral administration comprising azithromycin in an amount below that which causes gastrointestinal side effects, which dosage form is a controlled release dosage form.... | 03/05/2009 |
| 20080317846 | Pulsatile release histamine H2 antagonist dosage form A unit dosage form, such as a capsule or the like, for delivering drugs into the body in a circadian release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed. Each bead population exhibits a pre-design... | 12/25/2008 |
| 20080268043 | Controlled Release Compositions Comprising an Antipsychotic Agent The invention relates to a formulation for the treatment of acute manic episodes associated with Bipolar I Disorder comprising an antipsychotic agent selected from the group consisting of: a dibenzothiazepine derivative; lithium; and divalproex. The formulation comprise... | 10/30/2008 |
| 20080260819 | SUSTAINED RELEASE COMPOSITIONS OF DRUGS A sustained release pharmaceutical composition has been developed. The composition resists dose dumping when broken, crushed or chewed, which enhances the safety of the dosage form should it be accidentally or intentionally physically compromised. In the preferred embod... | 10/23/2008 |
